Quarterly Result29 Jul 2025, 02:04 pm
Jubilant Pharmova Reports Q1’FY26 Results: 10% Revenue Growth, EBITDA & PAT Margin Expansion
AI Summary
Jubilant Pharmova Limited reported its financial results for the quarter ended June 30, 2025. The company announced a 10% year-over-year (YoY) revenue growth, reaching Rs. 1,901 Cr. EBITDA grew by 14% YoY to Rs. 302 Cr. due to improved performance in CRDMO and Generics. Normalised PAT increased by 48% YoY to Rs. 103 Cr. on the back of improved operating performance and reduced finance cost. The company is investing in Radiopharma, CDMO Sterile Injectables, and CRDMO business to secure future growth, leading to a marginal increase in Net Debt / EBITDA from 1.1x in Mar’25 to 1.2x in Jun’25.
Key Highlights
- 10% YoY revenue growth to Rs. 1,901 Cr.
- 14% YoY EBITDA growth to Rs. 302 Cr.
- 48% YoY increase in normalised PAT to Rs. 103 Cr.
- Investments in Radiopharma, CDMO Sterile Injectables, and CRDMO business for future growth.
- Marginal increase in Net Debt / EBITDA from 1.1x in Mar’25 to 1.2x in Jun’25.